Analyst Naz Rahman of Maxim Group maintained a Buy rating on Nuvectis Pharma (NVCT – Research Report), retaining the price target of $17.00.
Naz Rahman has given his Buy rating due to a combination of factors including the promising interim data from Nuvectis Pharma’s Phase 1 trial of NXP900. The trial results demonstrated that NXP900 is well tolerated, with most adverse effects being minor and gastrointestinal in nature, and none requiring therapeutic intervention. Importantly, the 150mg dose achieved clinically relevant blood concentrations with over 90% Src inhibition, which is significant given the role of Src kinases in oncogenic pathways and therapeutic resistance.
Naz Rahman also highlights the potential of NXP900 to restore sensitivity to tumor cells against EGFR and ALK TKI inhibitors, which could lead to improved antitumor activity. The positive safety profile and meaningful Src inhibition suggest that NXP900 could be effective in combination therapies. With the Phase 1b study set to begin in summer 2025, Rahman remains optimistic about the risk-benefit profile of NXP900, supporting his Buy rating on Nuvectis Pharma’s stock.
Rahman covers the Healthcare sector, focusing on stocks such as Cingulate Inc, Galmed Pharmaceuticals, and Viking Therapeutics. According to TipRanks, Rahman has an average return of -24.1% and a 22.38% success rate on recommended stocks.
In another report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $15.00 price target.